Form 4/A for AUPH Aurinia Pharmaceuticals Inc.
Accepted 2024-02-22 00:00:00 ET · period of report 2023-03-02 · accession 0001600620-24-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2024-02-22 | 2023-03-02 | AUPH | Greenleaf Peter | CEO, Dir | S - Sale | $8.78 | -33.0K | 982.7K | -3% | -$290.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-02 | S | D | 33,047 | $8.78 | 982,671 | D | — | — | (F1) Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs. |